Johnson & Johnson CEO Alex Gorsky played down the potential fallout from U.S. politics on his company—and the rest of pharma, for that matter.

The PCSK9 cholesterol drugs got top billing at the American College of Cardiology meeting this year, but that doesn’t mean other studies didn’t rate.

President Donald Trump’s proposal to increase FDA user fees is already drawing some reaction from the industry.

Novartis has escaped a false advertising charge in Japan tied to questionable data on its heart drug Diovan. It was one of a series of missteps for the Swiss…

Sen. Bernie Sanders and Rep. Elijah Cummings have 'serious questions' for the FDA after its approval of Marathon's controversial Duchenne med…

Sen. Ron Wyden is diving into the contentious issue of pharmacy benefit manager rebates.

Endo's opioid painkiller Opana ER took a hit on Tuesday when an FDA advisory committee decided that the drug’s benefits no longer outweigh its risks.

Those who counted President Donald Trump an ally against vaccines might be disappointed in his pick to lead the FDA.

Regulatory